Page last updated: 2024-08-02 01:46:47

prostaglandin f2alpha 15-methyl ether

Description

prostaglandin F2alpha 15-methyl ether: retains considerable biological activity [MeSH]

Cross-References

ID SourceID
PubMed CID6441042
SCHEMBL ID18532333
MeSH IDM0095981

Synonyms (22)

Synonym
PDSP2_000737
pgf2alpha 15-methyl ether
(z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3s)-3-methoxyoct-1-enyl]cyclopentyl]hept-5-enoic acid
15-methoxyprostaglandin f2alpha
prostaglandin 15-methyl f2alpha
unii-are7bt6602
are7bt6602 ,
o-15-methylprostaglandin f2alpha ether
prosta-5,13-dien-1-oic acid, 9,11-dihydroxy-15-methoxy-, (5z,9alpha,11alpha,13e,15s)-
40834-96-6
prostaglandin f2-alpha 15-methyl ether
prostaglandin f2alpha 15-methyl ether
agn 191995
o-15-methylprostaglandin f2.alpha. ether
15-methoxyprostaglandin f2.alpha.
agn-191995
prosta-5,13-dien-1-oic acid, 9,11-dihydroxy-15-methoxy-, (5z,9.alpha.,11.alpha.,13e,15s)-
prostaglandin f2.alpha. 15-methyl ether
SCHEMBL18532333
Q27274081
DTXSID601149162
(5z,9alpha,11alpha,13e,15s)-9,11-dihydroxy-15-methoxyprosta-5,13-dien-1-oic acid

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (60.00)18.7374
1990's4 (26.67)18.2507
2000's2 (13.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (33.33%)5.53%
Reviews1 (6.67%)6.00%
Case Studies1 (6.67%)4.05%
Observational0 (0.00%)0.25%
Other8 (53.33%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
chlorinehalide anion;
monoatomic chlorine
cofactor;
Escherichia coli metabolite;
human metabolite
1982198242.0low010000
hydrogenelemental hydrogen;
elemental molecule;
gas molecular entity
antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
1982198242.0low010000
tyrosineamino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine
EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
1999199925.0low001000
methylergonovineergoline alkaloid2007200717.0low100100
mifepristone3-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound
abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
1995199529.0low101000
oxytocinheterodetic cyclic peptide;
peptide hormone
oxytocic;
vasodilator agent
1998199826.0low001000
dinoprostmonocarboxylic acid;
prostaglandins Falpha
human metabolite;
mouse metabolite
1981200734.1high594200
15-ketoprostaglandin f2alphaprostaglandins Falpha1981198143.0low010000
misoprostol2006200618.0low100100
arbaprostilprostanoid1982198242.0low010000
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Bernard-Soulier Syndrome01998199826.0low001000
Bleeding01985198539.0low010000
Blood Pressure, High01981198143.0low010000
Complications, Hematologic Pregnancy01998199826.0low001000
Delayed Postpartum Hemorrhage01981200726.0medium211200
Diarrhea01981198143.0low010000
Hemorrhage01985198539.0low010000
Hypertension01981198143.0low010000
Postpartum Hemorrhage01981200726.0medium211200
Pregnancy01981200732.8high574200

Dosage (1)

ArticleYear
Intramuscular administration of 15(S) methyl prostaglandins F2 alpha for midtrimester abortion.
Asia-Oceania journal of obstetrics and gynaecology, , Volume: 10, Issue:2
1984

Interactions (1)

ArticleYear
[Effect of 15-methyl PGF2 alpha methyl ester combined with tyrosine hydrazide on early pregnancy in mice].
Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, , Volume: 21, Issue:2
1999